BIOA (BIOA) Stock Analysis
Verdict: HOLD
A $188.9M cash buffer funds Phase 1 metabolic pipeline trials, but $82.4M annual burn and clinical trial execution risks demand caution.
Investment score: 46/100
The model views BioAge Labs as a high-risk clinical biotech with a strong $188.89M cash runway (~27.5 months) offset by steep technical downside momentum and early-stage pipeline risks.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| RLMD | -4.69 | 2.35 | 0.00 | -7.13 | — | 0.00 |
| NIKA | -5519.27 | -1303.95 | 0.00 | -5502.75 | — | 0.00 |
| AVIR | -2.53 | 2.06 | 0.00 | -2.01 | — | 0.00 |
| TTRX | -48.29 | 610.23 | 0.00 | -99.58 | — | 0.00 |
| PLTH.CN | -0.73 | 1.16 | 0.48 | -5.75 | — | -0.67 |